This study is being done to test how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) (FET) with positron emission tomography (PET) works in the imaging of tumors in the brain (intracranial tumors) that has come back after a period of improvement (recurrent), that is growing, spreading, or getting worse (progressive), or suspected. Imaging techniques play an important role in the clinical management of neuro-oncology patients. Anatomic imaging with magnetic resonance imaging (MRI) is the mainstay for initial diagnosis, treatment planning and post-treatment follow-up of brain tumors given its widespread availability, high spatial resolution and excellent soft tissue contrast. However, conventional MRI techniques have several important limitations in brain tumor imaging. FET is a radioactive drug that is taken up by tumor cells. FET is similar to the natural amino acid tyrosine. The radioactive part of the drug is fluorine-18 which allows scientist to see the amount of FET in the brain and in brain tumors over time. Brain tumors take up more amino acids than normal brain tissue, allowing scientist to see the tumor using PET. A PET scan is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Because cancer cells often take up more glucose than normal cells, the pictures can be used to find cancer cells in the body. Diagnostic procedures such as FET PET, may help doctors better image and characterize brain tumors.
Additional locations may be listed on ClinicalTrials.gov for NCT06474533.
Locations matching your search criteria
United States
California
San Francisco
University of California San FranciscoStatus: Active
Contact: Javier Villanueva-Meyer
Phone: 415-443-4916
PRIMARY OBJECTIVES:
I. To determine if FET PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1.
II. To determine if FET PET can accurately differentiate between low-grade and high-grade gliomas in population 2.
SECONDARY OBJECTIVES:
I. To determine if FET PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology or imaging follow-up in population 1.
II. To determine if FET PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1 patients with recurrent low-grade gliomas (grade 2).
EXPLORATORY OBJECTIVE:
I. To assess relationships between serial FET PET and clinical outcome (benign treatment-related changes and recurrence) in patients with recurrent metastatic lesion, recurrent high-grade gliomas and recurrent low grade gliomas).
OUTLINE: This is an observational study.
Patients receive FET intravenously (IV) over approximately 1 minute and undergo PET with computed tomography (CT) or MRI imaging over 40 minutes. Adult patients may undergo up to 2 additional FET PET with CT or MRI imaging on study. Patients' medical records are also reviewed.
After completion of study intervention, patients are followed up for 6 months.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationUniversity of California San Francisco
Principal InvestigatorJavier Villanueva-Meyer
